<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04578275</url>
  </required_header>
  <id_info>
    <org_study_id>STRATIFY-AF</org_study_id>
    <nct_id>NCT04578275</nct_id>
  </id_info>
  <brief_title>Atrial Fibrillation Stratification Based on the Arrhythmia Perpetuation Mechanisms</brief_title>
  <official_title>STRATIFY TRIAL: Atrial Fibrillation Stratification Based on the Arrhythmia Perpetuation Mechanisms.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Felipe Atienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitat Politècnica de València</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital General Universitario Gregorio Marañon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation treatments have a limited efficacy and often cause long-term side&#xD;
      effects. This study aims to develop and validate an ECGI system to risk stratification in&#xD;
      patients with persistent AF, identifying the mechanisms responsible for the maintenance and&#xD;
      the best treatment for ending it.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The MAIN GOAL of this project is to clinically validate the technology for the noninvasive&#xD;
      identification of the mechanisms responsible for maintenance of AF using ECGI. To achieve&#xD;
      this goal, the investigators will analyze the efficacy of different treatment options in&#xD;
      persistent AF patients as a function of the results of the ECGI. Mainly, patients will be&#xD;
      evaluated attending to the complexity of the patterns obtained. Moreover, the investigators&#xD;
      will evaluate the treatment benefit of performing guided-ablation in conjunction with&#xD;
      pulmonary vein isolation as compared to pulmonary vein isolation only. These analyses will be&#xD;
      performed in patients with persistent AF arriving at the clinic to determine treatment&#xD;
      options. AF outcomes following the treatment assigned therapy will be evaluated at 6 months&#xD;
      and 1 year after.&#xD;
&#xD;
      These parameters are obtained from the ECGI map: histogram of rotors (number of rotors and&#xD;
      location), Highest and Lowest Dominant Frequency (Hz), rotor duration (ms), simultaneous&#xD;
      rotors (number of rotors) and signal entropy (normalized).&#xD;
&#xD;
      Wide antrum circumferential pulmonary vein isolation with demonstration of bidirectional&#xD;
      block will be performed using standard cooled-tip radiofrequency catheters or cryoballoon&#xD;
      catheters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2018</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ECGI calculation of frecuency maps(Hz)</measure>
    <time_frame>12 months post-first intervention</time_frame>
    <description>Freedom from atrial fibrillation treated according to the ESC/AHA Atrial Fibrillation Guidelines in relation to the ECGI AF complexity score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECGI calculation of frecuency of rotor maps</measure>
    <time_frame>12 months post-first intervention</time_frame>
    <description>number of rotors mesasured Atrial Fibrillation Guidelines in relation to the ECGI AF complexity score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECGI AF complexity score calculated from the results of 1 and 2 to evaluate AF freedom from atrial fibrilation</measure>
    <time_frame>12 months post-first intervention</time_frame>
    <description>score calculated from the results of 1 and 2 to evaluate AF freedom from atrial fibrilation Atrial Fibrillation Guidelines in relation to the ECGI AF complexity score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from atrial fibrillation treated according to the ESC/AHA atrial fibrillation Guidelines evaluated in binary(0:AF Freedom;1:AF)</measure>
    <time_frame>12 months post-first intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from atrial fibrillation in patients undergoing rhythm control drug treatment.</measure>
    <time_frame>at 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from atrial fibrillation and other atrial arrhythmias in patients undergoing surgical AF ablation.</measure>
    <time_frame>at 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECGI calculations of Highest Dominant Frecuency(Hz)</measure>
    <time_frame>during ablation procedure and 12 months after</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECGI calculations of Lowest Dominant Frecuency(Hz)</measure>
    <time_frame>during ablation procedure and 12 months after</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECGI calculations of Rotor duration from rotor maps(ms)</measure>
    <time_frame>during ablation procedure and 12 months after</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECGI calculations of simultaneus number of rotors from rotor maps(ms)</measure>
    <time_frame>during ablation procedure and 12 months after</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ablation procedure duration</measure>
    <time_frame>Duration of ablation procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrophysiological characteristics of the Atrial fibrillation complexity</measure>
    <time_frame>Inclusion, rhythm vs rate treatment, ablation</time_frame>
    <description>Atrial fibrillation characteristics will be assesed according to the parameters obtained from ECGi calculations. These parameters are obtained from the frecuency maps(Hz) and histogram of rotors(number of rotors and location) and include : Highest and Lowest Dominant Frecuency(Hz), rotor duration(ms) and simultaneous rotors(number of rotors)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electroanatomic reconstruction and recordings of electrical activity</measure>
    <time_frame>During ablation procedure</time_frame>
    <description>a three-dimensional reconstruction of atrium and coronary sinus is obtained using high density catheters and an electroanatomic navigation system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy time</measure>
    <time_frame>During ablation procedure, in minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trained Neural Network based on ECGI signals</measure>
    <time_frame>6 and 12 month post-ablation outcome prediction</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic strategy using ECGI</intervention_name>
    <description>Procedure: Drug treatment, CVE, Pulmonary vein ablation isolation according to treatment guidelines and investigators discretion.&#xD;
ECGI: customized body surface mapping (57 electrodes) at the inclusion in the study, after treatment assignment and prior to AF ablation procedure.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        AF patients manifesting atrial fibrillation at the AF clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with paroxysmal AF symptomatic and refractory to at least one antiarrhythmic&#xD;
             medication arriving in atrial fibrillation to the AF clinic.&#xD;
&#xD;
          -  Patients with paroxysmal AF undergoing AF ablation in whom AF was induced at the EP&#xD;
             laboratory.&#xD;
&#xD;
          -  Patients with persistent AF or long-term persistent AF attending the AF clinic.&#xD;
&#xD;
          -  Patients must be able and willing to provide written informed consent to participate&#xD;
             in the study.&#xD;
&#xD;
          -  Prior anticoagulation for&gt; 4 weeks or transesophageal echocardiogram excluding&#xD;
             intracardiac thrombi.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with paroxysmal AF symptomatic and refractory to at least one antiarrhythmic&#xD;
             medication arriving in atrial fibrillation to the AF clinic.&#xD;
&#xD;
          -  Patients with paroxysmal AF undergoing AF ablation in whom AF was induced at the EP&#xD;
             laboratory.&#xD;
&#xD;
          -  Patients with persistent AF or long-term persistent AF attending the AF clinic.&#xD;
&#xD;
          -  Patients must be able and willing to provide written informed consent to participate&#xD;
             in the study.&#xD;
&#xD;
          -  Prior anticoagulation for&gt; 4 weeks or transesophageal echocardiogram excluding&#xD;
             intracardiac thrombi.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with inadequate anticoagulation levels, left atrial thrombus, tumor, or&#xD;
             another abnormality which precludes catheter introduction on TEE prior to the&#xD;
             procedure.&#xD;
&#xD;
          -  Patients with moderate-to-severe mitral regurgitation.&#xD;
&#xD;
          -  Patients with contraindications to systemic anticoagulation with heparin or coumadin.&#xD;
&#xD;
          -  Patients who are or may potentially be pregnant.&#xD;
&#xD;
          -  Current enrollment in another investigational drug or device study.&#xD;
&#xD;
          -  Pacemaker or Implantable Cardioverter Defibrillator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Felipe Atienza</last_name>
    <phone>+34914265028</phone>
    <email>fatienzaf@secardiologia.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>sandra vazquez</last_name>
    <phone>+34915868844</phone>
    <email>consultadeinvestigacioncardio@iisgm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Atienza, MD PhD</last_name>
      <phone>+34914265028</phone>
      <email>fatienzaf@secardiologia.es</email>
    </contact>
    <investigator>
      <last_name>Felipe Atienza, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Sanchez de la Nava, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 5, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>September 30, 2020</last_update_submitted>
  <last_update_submitted_qc>September 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General Universitario Gregorio Marañon</investigator_affiliation>
    <investigator_full_name>Felipe Atienza</investigator_full_name>
    <investigator_title>Head of cardiovascualar research and training, Cardiology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

